In particular, FDA approval of Rhopressa ® and Rocklatan ® and EMA approval of Rhokiinsa ® do not constitute regulatory approval of Rhopressa ® and Rocklatan ® in other jurisdictions, including EMA approval of Roclanda ®, and there can be no assurance that we will receive regulatory approval for Rhopressa ® and Rocklatan ® in such other jurisdictions, including EMA approval of Roclanda ®. In addition, FDA approval of Rhopressa ® and Rocklatan ® do not constitute FDA approval of our current or any future product candidates, and there can be no assurance that we will receive FDA approval for our current or any future product candidates. Furthermore, EMA acceptance of the MAA for Roclanda ® does not constitute EMA approval of Roclanda ®, and there can be no assurance that we will receive EMA approval of Roclanda ®.